New medication for the lower back pain could be “a gamuchanger” | Back pain

Millions of people worldwide with severe back pain may be able to get relief from A new drug This uses antibiotics rather than painkillers to tackle the condition.

Doctors who have tested the medication say that it could be “a gamschang” for those of four people, whose pain in the lower back is more likely to be caused by an infection than by muscle or spine problem.

A study in the early stages of the drug showed that six out of ten people who took it experienced great advantages, including a significant decline in pain and the disability they had previously suffered.

The drug, called PP353, is located in the development of Persica Pharmaceuticals, a biotech company in Kent. It carried out the process in connection with six NHS hospitals in England and Wales.

Dr. Shiva Tripathi, an NHS pain consultant and the chief searcher of the experiment, said when the medication is approved by the supervisory authorities and provides it [how] Antibiotics made a difference to infection. Because if we can bring these 25% of the patients with chronic pain in the lower back pain back to work, back to medication, back to a more disability, then I think [that] will be the massive gamechanger for the future. “

However, the randomized controlled study included only 44 patients -22 in Great Britain and 22 in Spain, Denmark and New Zealand -so that PP353 have to be subjected to further studies and have to be advocated by the drug wax dog before doctors can offer patients to alleviate their symptoms.

The patients had back pain at least six months and in some cases more than five years that had not reacted to conventional treatment such as pain medication.

Persica says that there is a great advantage of her treatment that the patient is two injections apart instead of having operated on or taking tablets for a long time. Youngest Research found The fact that most of the 56 ways of trying to relieve back pain that the researchers examined – from massage and acupuncture to pain relievers and physiotherapy – brought little or no real relief.

PP353 is a combination of three substances that are already widespread in medicine: Linezolid, an antibiotic; IOHEXOL, a contrast medium or dye; And a thermosensitive gel. It is injected into the lower back to banish an infection that has developed around the discs.

Steve Ruston, the company’s managing director, said: “Our first patient study has really achieved positive results. [It produced] significant reduction in pain and disability and [patients also saw] Clinically meaningful benefits and statistically significant use. The patient -good potential is enormous.

“If you can reduce the pain and disabilities that people live with as some of us [trial] The patients have reacted, it will change their lives. “

Market research shows that 2 million people in the United States and 250,000 to 300,000 in Great Britain could benefit from it, he added. “Millions of people around the world can benefit from it. But pain in the lower back is not just a problem in the first world. Everyone gets a lower back pain.”

The drug differs from other back pain, added Ruston, since it is more of the underlying cause of the problem than just the main symptom – pain.

Pain in the lower back is one of the most common health problems in the world. Six out of ten people in Great Britain will develop at some point. It is expected that it is growing as a problem worldwide due to the aging and growing population. It is often difficult to diagnose the cause and treat even more difficult.

Many patients in the study had a decline in pain that they suffered within one month of injections and still felt much better after a year, says Persica. However, Ruston added the need to continue to take painkillers, but not removed.

Dr. Benjamin Ellis, a consultant rheumatologist at Imperial Healthcare NHS Trust in London, who specializes in chronic pain, expressed skepticism about the potential of PP353.

“Modern medicine has largely failed people with chronic words, long-term back pain. However, there is hardly any evidence that interventions with operations or injections or even medication make a big difference for the vast majority of people with chronic back pain.

“People with chronic back pain are understandably desperate according to everything that can help. There is also a large industry in the delivery of technologies and medication that claim to help, but only a few evidence of this.

“Promising holistic approaches such as cognitive functional therapy often see no look at it, especially when the services are overloaded.

“Nevertheless, if there is a sub -group of people with chronic pain in the lower back that can benefit reliably and safely from a simple injection couple, that would be fantastic news – but it seems unlikely.”